Yinghui Shi

机构：Chinese PLA General Hospital

发表论文 29 篇 · 总被引 1147 次 · h-index 13

代表论文

• Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus (2021 · Nature Communications · 被引 200)
• Molecular characteristics and stages of chronic hepatitis B virus infection (2009 · World Journal of Gastroenterology · 被引 114)
• Helminth Protection against Autoimmune Diabetes in Nonobese Diabetic Mice Is Independent of a Type 2 Immune Shift and Requires TGF-β (2011 · The Journal of Immunology · 被引 99)
• Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis (2020 · Annals of the Rheumatic Diseases · 被引 93)
• Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes (2012 · Japanese Journal of Infectious Diseases · 被引 90)
• Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti‐IgE Monoclonal Antibody in Systemic Lupus Erythematosus (2018 · Arthritis & Rheumatology · 被引 63)